Integra Connect launches advanced analytics suite to help oncology practices improve cost-efficiency and quality of value-based cancer care
Oncology is the leading driver of cost in the healthcare industry today, increasing 88% (a rise of $20.7 billion) in the last five years. It is for this reason that oncologists need to be able to pull and analyze disparate clinical and financial data in a united format in order to predict high-impact interventions at patient and population levels to curb cost.
In response to this, Integra Connect today announced the availability of Integra Connect Intelligence™, a suite of advanced analytics to help oncology practices improve quality and cost through measures such as care navigation and care management against evidence-based plans. The need for advanced analytics solutions are prominent within the industry, in fact Virginia Cancer Institute, an independent group of 24 nationally-known oncologists, is already an early adapter of the tool and has begun seeing a significant impact on their insight into patient needs.
Intelligence enables analysis at the practice, site, provider, and patient levels across areas including:
– Quality of Care
– Cost and Utilization
– Predictive Analytics
– Care Bundle Episode Identification
“During the past year, our close collaboration with many of the nation’s pre-eminent oncology practices around the OCM has shed light on the greatest areas of uncertainty they face in successfully managing populations for value-based care,” said Charles Saunders, MD, CEO of Integra Connect. “It has also highlighted the obstacles presented by the inability to access and make sense of massive amounts patient data distributed across EHRs, claims, labs, pharmacy, and a host of other systems. With Integra Connect Intelligence, we unify and harmonize patient data and identify the highest-impact cost and quality improvement opportunities, all powered by proprietary algorithms and predictive models developed by our data science teams.”
Virginia Cancer Institute (VCI), an independent group of 24 nationally-known oncologists, is an early user of the advanced analytics solution.
“We are already working on the next generation of population health analytics capabilities to support our customers’ ongoing value-based care success,” continued Saunders. “With our data transaction and exchange engine in place, we will constantly broaden the data inputs – with a focus on genomic and molecular data – while producing insights that help realize the promise of precision medicine through personalized treatment options at the point of care.”
